Legend Biotech’s CD19/CD20 dual-target CAR T LB-2501 posted first-in-human updates at EHA2026 that aim to support development as an off-the-shelf, single-infusion, outpatient CAR T approach. Investigators reported that at the higher dose level, all six treated patients responded, including five complete responses. The program is notable for a safety profile that so far avoids neurotoxicity, with the highest adverse event grade reported as grade two. Legend CEO Ying Huang described the early tolerance as a “pleasant surprise” compared with autologous CAR T experiences where higher-grade adverse events occur in roughly 10% of patients. The presentation also followed other “viva in vivo” efforts, including updated data for Kelonia Therapeutics’ KLN-1010 at ASCO, where reported results included deepening responses and MRD negativity in the small cohort with evaluable data. Together, the readouts highlight momentum toward reducing inpatient burden in CAR T delivery models.